ArticleTurkish journal of medical sciences2026
Oleanolic acid-chitosan compound inhibits mitochondrial autophagy and malignant transformation of lung cancer through the PTEN/AKT pathway.
Article in Turkish journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Oleanolic acid-chitosan compound (OAC) shows potent antinonsmall cell lung cancer (NSCLC) activity, but its mechanisms remain unclear. This study elucidates how OAC modulates autophagy and apoptosis via the Phosphatase and Tensin Homolog/Protein Kinase B (PTEN/AKT) signaling pathway. Materials and methods: Oleanolic acid was coupled with chitosan to synthesize OAC. A549 and MRC-5 cells were cultured in Dulbecco's Modified Eagle Medium and Minimum Essential Medium, respectively, supplemented with 10% fetal bovine serum and penicillin-streptomycin. Cells were pretreated with chloroquine before OAC treatment. Cell viability was assessed using the CCK-8 assay, while 5-bromo-2'-deoxyuridine (BrdU) and colony formation tests were employed to evaluate cell proliferation. Apoptosis was measured by flow cytometry using Annexin V-FITC/PI (fluorescein isothiocyanate/propidium iodide) staining. Autophagy was monitored through western blot analysis of LC3, SQSTM1, Atg5, Beclin1, and LAMP1, and confirmed by immunofluorescence and transmission electron microscopy (TEM). Mitochondrial membrane potential (MMP) was determined by JC-1 staining, and acridine orange staining was used to detect acidic vesicular organelles (AVOs). Additionally, PTEN overexpression was induced by transfecting cells with the hemagglutinin tag (HA)-PTEN plasmid. Results: OAC treatment significantly inhibited cell viability and proliferation in A549 cells, as evidenced by decreased CCK-8 absorbance, reduced BrdU incorporation, and fewer colony formations. Flow cytometry revealed a marked increase in apoptotic cells following OAC treatment. Western blot analysis demonstrated altered expression levels of apoptosis-related proteins (Bcl-2, Bax, Cytochrome c, caspase-9, caspase-3, PARP) and autophagy markers (LC3, SQSTM1, Atg5, Beclin1, LAMP1). Immunofluorescence and TEM further confirmed the induction of autophagy. AO staining showed increased AVOs, while JC-1 staining indicated a reduction in MMP. PTEN overexpression enhanced OAC-induced apoptosis and autophagy. Conclusion: OAC effectively inhibits cell proliferation and induces apoptosis and autophagy in A549 cells, with PTEN playing a regulatory role in these processes. These findings suggest that OAC may serve as a potential therapeutic agent for cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.